Business News • PR NewsWire • MabVax Therapeutics ImmunoPET Imaging Agent MVT-2163 to be Featured in Two Presentations at the 2017 SNMMI Annual Meeting

MabVax Therapeutics ImmunoPET Imaging Agent MVT-2163 to be Featured in Two Presentations at the 2017 SNMMI Annual Meeting

MabVax Therapeutics ImmunoPET Imaging Agent MVT-2163 to be Featured in Two Presentations at the 2017 SNMMI Annual Meeting

SAN DIEGO, June 7, 2017 /PRNewswire/ -- MabVax Therapeutics Holdings, Inc. (Nasdaq: MBVX), a clinical-stage biotechnology company with a fully human antibody discovery platform focused on the rapid translation into clinical development of products to address unmet medical needs in the...

View More : http://www.prnewswire.com/news-releases/mabvax-therapeutics-immunopet-imaging-agent-mvt-2163-to-be-featured-in-two-prese...

Releted News by prnewswire

Zenedge Launches Advanced API Security Solution with Native SDK for Web and Mobile

TraceLink Unveils Industry's First Compliance and Digital Information Platform for Pharmacies with EU FMD Requirements

L'entreprise chinoise Banner Dairy décroche la récompense suprême aux Monde Selection Awards 2017

MabVax Therapeutics ImmunoPET Imaging Agent MVT-2163 to be Featured in Two Presentations at the 2017 SNMMI Annual Meeting

RXi Pharmaceuticals Corporation Announces the Appointment of Dr. Jonathan Freeman to its Board of Directors